JLE

Hépato-Gastro & Oncologie Digestive

MENU

Impact des tumeurs neuroendocrines digestives et de leurs traitements sur la qualité de vie des patients Volume 26, supplément 5, Décembre 2019

  • [1] Dasari A., Shen C., Halperin D. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335-1342.
  • [2] Halperin D.M., Shen C., Dasari A. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017;18:525-534.
  • [3] Frojd C., Larsson G., Lampic C., von Essen L. Health related quality of life and psychosocial function among patients with carcinoid tumours. A longitudinal, prospective, and comparative study. Health Qual Life Outcomes. 2007;5:18.
  • [4] Haugland T., Vatn M.H., Veenstra M. Health related quality of life in patients with neuroendocrine tumors compared with the general Norwegian population. Qual Life Res. 2009;18:719-726.
  • [5] Pezzilli R., Campana D., Morselli-Labate A.M. Patient-reported outcomes in subjects with neuroendocrine tumors of the pancreas. World J Gastroenterol. 2009;15:5067-5073.
  • [6] Beaumont JL, Cella D, Phan AT, et al. Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas 2012 ; 41 : 461-466.
  • [7] Cadiot G, Baudin E, Coriat R, et al. Tumeurs neuro-endocrines. Thésaurus National de Cancérologie Digestive, 12-10-2017.
  • [8] Ruszniewski P., Valle J.W., Lombard-Bohas C. Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study. Dig Liver Dis. 2016;48:552-558.
  • [9] Caplin ME, Pavel M, Cwikla JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014 ; 371 : 224-233.
  • [10] Rinke A., Muller H.H., Schade-Brittinger C. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656-4663.
  • [11] Rinke A, Neary MP, Eriksson J, et al. Health-related quality of life for long-acting octreotide versus placebo in patients with metastatic midgut neuroendocrine tumors in the phase 3 PROMID Trial. Neuroendocrinology 2019 ; 109 : 141-151.
  • [12] Yao J.C., Fazio N., Singh S. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): A randomised, placebo-controlled, phase 3 study. Lancet. 2016;387:968-977.
  • [13] Pavel ME, Singh S, Strosberg JR, et al. Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2017 ; 18: 1411-1422.
  • [14] Raymond E., Dahan L., Raoul J.L. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501-513.
  • [15] Vinik A, Bottomley A, Korytowsky B, et al. Patient-reported outcomes and quality of life with sunitinib versus placebo for pancreatic neuroendocrine tumors: Results from an international phase III trial. Target Oncol 2016 ; 11 : 815-824.
  • [16] Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of (177)lu-dotatate for midgut neuroendocrine tumors. N Engl J Med 2017 ; 376 : 125-135.
  • [17] Strosberg J, Wolin E, Chasen B, et al. Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with (177)lu-dotatate in the phase III NETTER-1 trial. J Clin Oncol 2018 ; 36 : 2578-2584.
  • [18] Plante A, Baudin E, Do Cao C, et al. Patient-reported tolerance in treatments approved in neuroendocrine tumors: A national survey from the French Group of Endocrine Tumors. Clin Res Hepatol Gastroenterol 2018 ; 42 : 153-159.